News

MAP Pharmaceuticals has announced plans to present analysis of data from the efficacy portion of the first phase 3 trial of its novel Levadex orally inhaled migraine therapy,

Esperance Pharmaceuticals has begun enrollment and dosing of patients in a phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the candidate from Esperance’s Cationic

GATC Biotech has announced that the mayor Claus Boldt, architect Hans-Peter Engelmann and CEO Peter Pohl, officially initiated the first sod, marking the beginning of the expansion of

Vical’s DNA vaccine against A/H1N1 pandemic influenza (swine flu) has demonstrated robust immune responses in all of vaccinated animals against virus strains isolated from recent outbreaks in three

Acorda Therapeutics has announced the data for interim analysis of two-year efficacy and safety data from phase 3 Fampridine-SR extension study. The open-label extension study for Fampridine-SR trial,

Global Med Technologies, an international e-Health, medical information technology company, has announced that its Wyndgate Technologies division has licensed and deployed its SafeTrace Tx transfusion management software to

GenScript has signed biology research collaboration with Roche R&D Center (RRDCC), a subsidiary of Roche since early 2009. Under the agreement, GenScript is set to provide assay development

Par Pharmaceutical has received final approval from the FDA for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis’ Starlix. The company

Law Offices of Howard G Smith has filed class action lawsuit in the Court of Chancery for the State of Delaware on behalf of all public stockholders who